FIELD: oncology. SUBSTANCE: invention provides soluble antibody conjugate capable of activating cytotoxic T cells, which can be applied in treatment of oncologic diseases. EFFECT: extended source of recombinant technique-prepared antineoplastic means. 30 cl, 4 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE ELICITING ABILITY TO ACTIVATE IMMUNE SYSTEM AND PHARMACEUTICAL COMPOSITION COMPRISING INDICATED CONJUGATE | 1997 |
|
RU2198895C2 |
| CONJUGATE TO STIMULATE IMMUNE RESPONSE AGAINST A TARGET CELL, METHOD TO TREAT MALIGNANT TUMORS IN MAMMALIANS | 1995 |
|
RU2183215C2 |
| NOVEL BIOTECHNOLOGICALLY CREATED SUPERANTIGEN FOR TREATING HUMANS | 2002 |
|
RU2307837C2 |
| ANTIBODY RAISED AGAINST TO HUMAN GASTROENTERIC TRACT EPITHELIAL TUMOR ANTIGEN RELATED WITH ALPHA-6,BETA-4-INTEGRIN | 2000 |
|
RU2266298C2 |
| NEW ANTIBODY SHOWING SPECIFICITY TO MALIGNANT LARGE INTESTINE TUMOR | 2001 |
|
RU2268068C2 |
| BIOLOGICAL MATERIALS AND APPLICATION THEREOF | 2006 |
|
RU2432363C9 |
| ANTIBODY DRUG CONJUGATES | 2014 |
|
RU2669812C2 |
| HUMAN ANTIBODIES AND CONJUGATES OF ANTIBODY-PREPARATION AGAINST CD74 | 2012 |
|
RU2636029C2 |
| COMBINED THERAPY WITH ANTI-CD20 ANTIBODIES TYPE I AND TYPE II | 2008 |
|
RU2595383C2 |
| CONJUGATION METHODS | 2010 |
|
RU2765240C2 |
